Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
screening for reproductive / developmental toxicity
Remarks:
Range finding study
Type of information:
experimental study
Adequacy of study:
key study
Study period:
21 September to 11 December 2017
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2017
Report date:
2017

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
Version / remarks:
Range finding study
Deviations:
no
GLP compliance:
no
Remarks:
Study was a range finding study and was not conducted to full GLP requirements.
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
p-vinylphenol
EC Number:
220-103-6
EC Name:
p-vinylphenol
Cas Number:
2628-17-3
Molecular formula:
C8H8O
IUPAC Name:
p-vinylphenol
Test material form:
solid: particulate/powder
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material:
Maruzen Petrochemical Co.Ltd./ Bx 7831WJD
- Expiration date of the lot/batch:
- Purity test date:

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material:
Opaque airtight container at -30°C to -10°C
- Stability under test conditions:
Stable
- Solubility and stability of the test substance in the solvent/vehicle:
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium:

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing:
- Preliminary purification step (if any):
- Final dilution of a dissolved solid, stock liquid or gel:
- Final preparation of a solid:

FORM AS APPLIED IN THE TEST (if different from that of starting material)

TYPE OF BIOCIDE/PESTICIDE FORMULATION (if applicable)

OTHER SPECIFICS:

Test animals

Species:
rat
Strain:
Crj: CD(SD)
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source:
Commercial laboratory animal supplier.
- Females: nulliparous and non-pregnant: yes
- Age at study initiation:
7 weeks
- Weight at study initiation:

- Fasting period before study:
- Housing:
Barrier-system animal rooms
- Diet:
autoclaved pelleted diet ad libitum.
- Water:. ad libitum
- Acclimation period: 6 days


DETAILS OF FOOD AND WATER QUALITY:

ENVIRONMENTAL CONDITIONS
- Temperature (°C):
21 - 25°C
- Humidity (%):
40 - 70%
- Air changes (per hr):
10-15
- Photoperiod: 12hrs dark / 12hrs light

IN-LIFE DATES: From: To:

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
other: gum arabic
Details on exposure:
The animals were orally treated by gavage for 14 days daily with a syringe connected to a catheter at dosing volumes of 5 ml/Kg based on body weight
Details on mating procedure:
None, toxic effect meant mating would not take place
Analytical verification of doses or concentrations:
yes
Duration of treatment / exposure:
The animals were orally treated by gavage for 14 days daily with a syringe connected to a catheter at dosing volumes of 5 ml/Kg based on body weight
Frequency of treatment:
Daily
Doses / concentrationsopen allclose all
Dose / conc.:
0 mg/kg bw/day (actual dose received)
Remarks:
Control
Dose / conc.:
50 mg/kg bw/day (actual dose received)
Remarks:
low dose
Dose / conc.:
200 mg/kg bw/day (actual dose received)
Dose / conc.:
500 mg/kg bw/day (actual dose received)
Dose / conc.:
1 000 mg/kg bw/day (actual dose received)
No. of animals per sex per dose:
3
Control animals:
yes
yes, concurrent no treatment

Examinations

Parental animals: Observations and examinations:
Daily before and after dosing
Postmortem examinations (parental animals):
In males, salivation, prone position, colonic convulsions, decrease spontaneous locomotion, lacriamtion, incomplete eyelid opening were observed and all animals were dead in the 1000 mg/kg.bw group on day 1.
Salivation, prone position, colonic convulsions, decrease spontaneous locomotion, lacriamtion, incomplete eyelid opening were observed and all animals were dead in the 500 mg/kg.bw group on day 1.
Salivation, prone position, colonic convulsions, decrease spontaneous locomotion, lacriamtion, incomplete eyelid opening were observed and all animals were dead in the 200 mg/kg.bw group on day 1.
Decreased spontaneous locomotion and decreased respiratory rate were observed in one of the 50mg/kg group from day 2 to day 4.

In females, prone position, lateral position, colonic convulsion, decreased spontaneous locomotion, incomplete eyelid opening were observed and all animals died in the 1000 mg/kg group on day 1.
Salivation, lateral position,colonic convulsion, decreased spontaneous locomotion, incomplete eyelid opening were observed and all animals died in the 500 mg/kg group.
Decreased spontaneous locomotion, lacrimation, incomplete eyelid opening, decreased respiratory rate, sub-normal temperature were observed in the 200 mg/kg group on day 1.One animal in the 200 mg/kg group hada shuffling gate from day 2 and salivation, anorexia, decreased stool volume were observed on day 3 and this animal was euthanised on day 3. No abnormalities were observed in the 50 mg/kg group.

Results and discussion

Results: P0 (first parental generation)

General toxicity (P0)

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
In males, salivation, prone position, colonic convulsions, decrease spontaneous locomotion, lacriamtion, incomplete eyelid opening were observed and all animals were dead in the 1000 mg/kg.bw group on day 1.
Salivation, prone position, colonic convulsions, decrease spontaneous locomotion, lacriamtion, incomplete eyelid opening were observed and all animals were dead in the 500 mg/kg.bw group on day 1.
Salivation, prone position, colonic convulsions, decrease spontaneous locomotion, lacriamtion, incomplete eyelid opening were observed and all animals were dead in the 200 mg/kg.bw group on day 1.
Decreased spontaneous locomotion and decreased respiratory rate were observed in one of the 50mg/kg group from day 2 to day 4.

In females, prone position, lateral position, colonic convulsion, decreased spontaneous locomotion, incomplete eyelid opening were observed and all animals died in the 1000 mg/kg group on day 1.
Salivation, lateral position,colonic convulsion, decreased spontaneous locomotion, incomplete eyelid opening were observed and all animals died in the 500 mg/kg group.
Decreased spontaneous locomotion, lacrimation, incomplete eyelid opening, decreased respiratory rate, sub-normal temperature were observed in the 200 mg/kg group on day 1.One animal in the 200 mg/kg group hada shuffling gate from day 2 and salivation, anorexia, decreased stool volume were observed on day 3 and this animal was euthanised on day 3. No abnormalities were observed in the 50 mg/kg group.
Dermal irritation (if dermal study):
not examined
Mortality:
mortality observed, treatment-related
Description (incidence):
Mortality occured at 500 and 1000 mg/kg doses.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
For males decreased body weigh was observed in the 200 mg/kg group. No affect was observed on the 50mg/kg group.

In feamales, decreased body weigths were observed in 200 and 50 mg/kg groups.
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
effects observed, treatment-related
Immunological findings:
no effects observed
Organ weight findings including organ / body weight ratios:
no effects observed
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined

Reproductive function / performance (P0)

Reproductive function: oestrous cycle:
not examined
Reproductive function: sperm measures:
not examined
Reproductive performance:
not examined

Effect levels (P0)

Key result
Dose descriptor:
NOAEL
Effect level:
ca. 50 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male
Basis for effect level:
clinical signs

Target system / organ toxicity (P0)

open allclose all
Key result
Critical effects observed:
yes
Lowest effective dose / conc.:
50 mg/kg bw/day (actual dose received)
System:
central nervous system
Organ:
spinal cord
Treatment related:
yes
Dose response relationship:
not specified
Relevant for humans:
yes
Key result
Critical effects observed:
yes
Lowest effective dose / conc.:
50 mg/kg bw/day (actual dose received)
System:
gastrointestinal tract
Organ:
colon
duodenum
ileum
intestine
jejunum
oesophagus
oral cavity
rectum
stomach
tongue
Treatment related:
yes
Dose response relationship:
yes
Relevant for humans:
yes
Key result
Critical effects observed:
yes
Lowest effective dose / conc.:
50 mg/kg bw/day (actual dose received)
System:
nervous system
Organ:
forebrain
neurons
spinal cord
Treatment related:
yes
Dose response relationship:
yes
Relevant for humans:
yes
Key result
Critical effects observed:
yes
Lowest effective dose / conc.:
50 mg/kg bw/day (actual dose received)
System:
urinary
Organ:
bladder
kidney
ureter
urethra
Treatment related:
yes
Dose response relationship:
yes
Relevant for humans:
yes

Results: P1 (second parental generation)

General toxicity (P1)

Clinical signs:
not examined
Dermal irritation (if dermal study):
not examined
Mortality:
not examined
Body weight and weight changes:
not examined
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
not examined
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Other effects:
not examined

Reproductive function / performance (P1)

Reproductive function: oestrous cycle:
not examined
Reproductive function: sperm measures:
not examined
Reproductive performance:
not examined

Effect levels (P1)

Key result
Dose descriptor:
NOAEL
Effect level:
> 0 mg/kg bw/day (actual dose received)
Based on:
test mat. (total fraction)
Sex:
male/female
Basis for effect level:
clinical signs
mortality
gross pathology
Remarks on result:
not determinable due to adverse toxic effects at highest dose / concentration tested

Results: F1 generation

General toxicity (F1)

Clinical signs:
not examined
Mortality / viability:
not examined
Body weight and weight changes:
not examined
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Sexual maturation:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
not examined
Histopathological findings:
not examined
Other effects:
not examined

Developmental neurotoxicity (F1)

Behaviour (functional findings):
not examined

Developmental immunotoxicity (F1)

Developmental immunotoxicity:
not examined

Effect levels (F1)

Key result
Dose descriptor:
NOAEL
Generation:
other: Not tested
Effect level:
> 0 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
viability
mortality
Remarks on result:
not determinable due to adverse toxic effects at highest dose / concentration tested

Results: F2 generation

General toxicity (F2)

Clinical signs:
not examined
Mortality / viability:
not examined
Body weight and weight changes:
not examined
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Sexual maturation:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
not examined
Histopathological findings:
not examined
Other effects:
not examined

Developmental neurotoxicity (F2)

Behaviour (functional findings):
not examined

Developmental immunotoxicity (F2)

Developmental immunotoxicity:
not examined

Effect levels (F2)

Key result
Dose descriptor:
NOAEL
Generation:
other: not tested
Effect level:
> 0 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
viability
mortality
Remarks on result:
not determinable due to adverse toxic effects at highest dose / concentration tested

Overall reproductive toxicity

Key result
Reproductive effects observed:
yes
Lowest effective dose / conc.:
50 mg/kg bw/day (actual dose received)
Treatment related:
yes
Relation to other toxic effects:
reproductive effects occurring together with other toxic effects, but not as a secondary non-specific consequence of other toxic effects
Dose response relationship:
yes
Relevant for humans:
yes

Any other information on results incl. tables

Male animals were not capable of reproduction at the low dose of 50mg/kg/bw

Applicant's summary and conclusion

Conclusions:
The toxic changes in this fourteen day study are similar to those of phenol (EC 203-632-7 CAS 108-95-2), corrosive and chemical burns at contact site, transient CNS stimulation followed by CNS depression, coma, seizures, diarrhea, methemoglobinemia, etc. Reference should be made to Agency for Toxic Substances and Disease Registry (USA) Medical Management Guidelines for Phenol mmg115 2017.

Due to the toxic effects coninuation of the study will only lead to unecessary suffering of more animals